Depixus, a pioneer in the field of intereactomics, has been awarded the prestigious Society for Laboratory Automation and Screening (SLAS) Ignite Award at the society’s annual International Conference and Exhibition in Boston, MA. The award was presented to the company in recognition of their groundbreaking MAGNA™ technology.
The Ignite Award is given to companies that are revolutionizing the life sciences with their innovative technologies. Participants were evaluated by a panel of experts on various criteria including excellence in innovation, marketing presence, impact, funding, and balanced leadership. Depixus was one of just 16 companies selected to participate in the SLAS2024 Innovation AveNEW program, which is a dedicated area for start-ups and emerging companies within the conference. From this group of 16 companies, Depixus was chosen as one of the top eight finalists for the Ignite Award.
MAGNA One is based on magnetic force spectroscopy and enables high-throughput analysis of dynamic biomolecular interactions. This technology offers real-time measurements from thousands of individual molecules simultaneously, making it particularly useful for exploring challenging targets such as RNA and protein-protein interactions. It provides valuable insights into disease mechanisms and accelerates the development of novel therapeutics.
Depixus CEO Gordon Hamilton expressed his excitement about winning the Ignite Award, emphasizing the company’s innovative technology and its potential to impact the understanding and treatment of diseases where new treatments are urgently needed. Chief Commercial Officer Steve Klose added that this momentous occasion coincides with both their technology access program launch and commercial rollout of MAGNA One – a significant milestone for Depixus’ growth as a company.
For more information about Depixus or MAGNA One technology, visit depixus.com or contact Steve Klose at firstname.lastname@example.org